Clinical Research Directory

Inclusion Criteria: * Age 18 years old and older * Cancer survivors with no evidence of disease (cancer); * Completed neurotoxic chemotherapy, i.e., platinum agents, taxanes, vinca alkaloids, and bortezomib, at least three months before enrollment; * A CIPN diagnosis based on symptom history, loss of deep tendon reflexes, or presence of symmetrical stocking-glove pain, numbness, or paresthesia; * Answers "yes" to the following question: "Do you feel as though your balance is affected from experiencing CIPN?" or "Are you afraid of falling as a result of your CIPN?"; * On a stable regimen (no change in past three months) if taking anti-neuropathy or other pain medications; * Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤ 2 * Willing to adhere to all study-related procedures, including randomization to the Tai Chi or waitlist group, 2 in-person visits to Dana-Farber Cancer Institute (DFCI) (one within 2 weeks of enrollment and one at week 12); * Willing to adhere to requirement that no new pain medication be taken throughout the study period; and * Individuals receiving endocrine therapy or targeted/antibody therapy, such as trastuzumab, pertuzumab, or immunotherapy, will be eligible to participate. Exclusion Criteria: • Patients who have received physical therapy or Tai Chi training, specifically for CIPN, in the past three months.